Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
Abstract Data suggest that for newly approved cancer drugs safety and tolerability are worse than in control arms of registration trials. Less is known about the balance between efficacy and toxicity of drugs studied in unselected phase 3 randomized controlled trials (RCTs) including those not resul...
Main Authors: | Domen Ribnikar, Hadar Goldvaser, Zachary W. Veitch, Alberto Ocana, Arnoud J. Templeton, Boštjan Šeruga, Eitan Amir |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-90403-3 |
Similar Items
-
Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
by: Ramy R. Saleh, et al.
Published: (2020-11-01) -
Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
by: Mustafa Al-Mubarak, et al.
Published: (2014-01-01) -
Air safety--the last decade
by: Wang, Alexander Ning-Yuan
Published: (2008) -
Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
by: Zist Andrej, et al.
Published: (2015-12-01) -
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
by: Amirrtha Srikanthan, et al.
Published: (2015-01-01)